MaxCyte fell 24.7% from $1.70 to $1.28, behind the S&P 500's +8.0%. Its worst day was Dec 3 (−13.6%), and its low came Mar 30 at $0.68.
Story events cover the past 12 months · Times ET
Nov 19, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
MaxCyte closed at its highest level of the year, 3.5% above where the year started.
+0.6% · S&P 500 +0.5%
EPS of $-0.09 missed the $-0.08 estimate on $7.3M revenue (est. $9.2M); FY revenue guidance of $30.0M–$32.0M against the $38.1M consensus.
−6.8% · S&P 500 +0.6%
EPS of $-0.04 beat the $-0.09 estimate on $9.7M revenue (est. $7.3M); FY revenue guidance of $30.0M–$32.0M against the $30.8M consensus.
+24.1% · S&P 500 +0.6%
EPS of $-0.08 beat the $-0.10 estimate on $7.3M revenue (est. $6.5M); FY revenue guidance of $30.0M–$32.0M against the $31.1M consensus.
+9.4% · S&P 500 +0.7%
MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today
+29.6%, the year's best day · S&P 500 −1.1%
EPS of $-0.05 beat the $-0.08 estimate on $10.2M revenue (est. $7.4M); FY revenue guidance of $34.5M against the $32.2M consensus.
−13.1% · S&P 500 −0.4%
Where it ended: a close of $1.28 on Nov 19, 2026.
Nothing in the past 12 months.
All MXCT dividend history